Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US34962G2084
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001J2N4H0
FBRX
Forte Biosciences, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Forte Biosciences, Inc.
ISIN
US34962G2084
TICKER
FBRX
MIC
XNAS
REUTERS
FBRX.OQ
BLOOMBERG
FBRX US
Di., 04.08.2026       Forte Biosciences
US34962G2084

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basi...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Forte Biosciences
US34962G2084

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Forte Biosciences
US34962G2084

NEW YORK, July 27, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Forte Biosciences
US34962G2084

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersade...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Forte Biosciences
US34962G2084

MILWAUKEE, July 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Forte (Nasdaq: FBRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with argenx. Click here to learn how to join our investigation and obtain additional info...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Forte Biosciences
US34962G2084

argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc.  (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102,...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 09.07.2026       Forte Biosciences
US34962G2084

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value =...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       Forte Biosciences
US34962G2084

Instrument ID [20756362] (37T - US34962G2084) suspended...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 27.08.2024       Forte Biosciences
US34962G2084

Das Instrument 37T US34962G2084 FORTE BIOSCIENCES INC. EQUITY hat seinen ersten Handelstag am 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument 37T US34962G2084 FORTE BIOSCIENCES INC. EQUITY has its first trading date on 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
Zur Nachricht
Forte Biosciences
Charts & Research Termsheets Terminal
Permalink